Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Organisation › Details

Selvita S.A. (WSE:SLV)

Selvita is a drug discovery company, developing breakthrough therapies in the area of oncology. The company’s most advanced program, SEL24, has been licensed to Menarini Group and is currently in Phase I studies in AML. Other projects include SEL120, a first-in-class small molecule inhibitor of CDK8 in preclinical studies, several drug discovery platforms in immuno-oncology, immunometabolism and cancer metabolism, as well as epigenetics, performed independently or in collaboration with global pharma and biotech companies. Selvita also offers a broad range of integrated drug discovery services, helping biotech and pharma partners discover and develop new drugs. The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Menarini Group, Leukemia and Lymphoma Society, Merck, H3 Biomedicine, and Nodthera. The company was established in 2007 and currently employs over 446 scientists, among which 30% are PhDs. Selvita is headquartered in Krakow with second research site in Poznan, Poland and international offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK. Selvita is listed on the Warsaw Stock Exchange (WSE:SLV). *


Period Start 2011-06-01 renamed date ca
  Group Selvita (Group)
  Predecessor Selvita Sp. z o.o.
Products Industry drug discovery services
  Industry 2 chemical services
Persons Person Przewiezlikowski, Pawel (Selvita 201309 CEO + Co-Founder)
  Person 2 Sieczkowski, Boguslaw (Selvita 201405 CFO + Co-Founder + key shareholder)
Region Region Kraków
  Country Poland
  Street 14 ul. Bobrzynskiego
Park Life Science
  City 30348 Kraków
  Tel +48-12-297-4700
    Address record changed: 2019-08-09
Basic data Employees D: 101 to 500 (2018-02-16)
  Currency EUR
  Annual sales 9,805,000 (revenues, total, consolidated (2015) 2015-12-31)
  Profit 1,490,000 (2015-12-31)
  Cash 6,760,000 (2015-12-31)
    * Document for ďż˝About Sectionďż˝: Selvita S.A.. (2/16/18). "Press Release: Selvita Announces Successful Completion of $41 M Book Building [ NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN ]". Kraków.
Record changed: 2019-05-23


Picture [iito] Plain Stupid Simple 650x80px

More documents for Selvita (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top